USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: Vertex Pharmaceuticals Inc.
City: Cambridge
State: MA
Zip+4: 02139
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $249,336.00 5
SBIR Phase II $800,000.00 2

Award List:

SUBSTRATES FOR PEPTIDYL PROLYL CIS-TRANS ISOMERASE ASSAYS

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Roger D Tung
Award Amount: $50,000.00
Abstract:
Recent reports have indicated that fk-506, a novel, highly potent immunosuppressant, is an effective agent for preventing organ transplant rejection in humans that displays a different toxicity profile than cyclosporin a (csa). a major fk-506 binding protein, fkbp, has been shownto be a… More

HUMAN CDNA/GENE FOR AN IMMUNOSUPPRESSANT-BINDING PROTEIN

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Debra A Peattie
Award Amount: $49,955.00

NOVEL ENZYME IMMOBILIZATION FOR BIOSENSOR APPLICATIONS (BACTERIA)

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Navia, Manuel A , Principal Investigator
Award Amount: $49,825.00
Abstract:
Enzyme crystals, cross-linked using a bifunctional reagent such as glutaraldehyde, constitute a novel form of enzyme immobilization. such cross-linked immobilized enzyme crystals (cliecs) are superior to conven- tionally immobilized enzymes in many respects. for example, the crystal lattice… More

HUMAN CDNA/GENE FOR AN IMMUNOSUPPRESSANT-BINDING PROTEIN

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: HHS
Principal Investigator: Debra A Peattie
Award Amount: $500,000.00
Abstract:
This phase i project will conduct experiments to initiate molecular analysis of the human cdna and gene encoding fk-506 binding protein (fk-506 bp), a cytosolic protein thatbinds the potent immunosuppressor fk-506. fk-506 is a recently discovered immunosuppressive compound that is significantly more… More

NON-VIRAL, HUMAN T CELL ASSAY FOR HIV-1 PROTEASE

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael S Su
Award Amount: $50,000.00
Abstract:
Acquired immune deficiency syndrome (aids) is an enormous health threat. the causative agent on aids is the hiv-1 virus. consequently, there is an ongoing effort towards identifying novel anti-hiv-1 therapeutics. one potent anti-hiv-1 target is the virally-encoded protease (prt), which is essential… More

CROSSLINKED ENZYME CRYSTALS AS CATALYSTS IN ORGANIC SYNTHESIS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: NSF
Principal Investigator: Dr. Manuel Navia , Senior Scientist
Award Amount: $49,556.00

CROSSLINKED ENZYME CRYSTALS AS CATALYSTS IN ORGANIC SYNTHESIS

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: NSF
Principal Investigator: Dr. Manuel Navia , Senior Scientist
Award Amount: $300,000.00
Abstract:
Enzyme catalyzed processes offer significant advantages overtraditional chemical methods in organic syntheses, includingsuperior efficiency, stereoselectivity and specificity. however, soluble and conventionally immobilized enzymes are often inactive under typical laboratory or manufacturing… More